Resources
About Us
Home Report
Store
Diagnostic Specialty Antibodies Market
Diagnostic Specialty Antibodies Market by Type (Primary, Secondary), Clonality (Monoclonal, Polyclonal), Technique (WB, Rapid Test, IHC, IP), Conjugate, and Application (Dengue, Malaria, Hepatitis, HIV, E. coli , Tuberculosis, Pneumonia, Cancer)- Forecast to 2029
Report ID:MRHC - 104554 Pages: 290 Apr-2022 Formats*: PDF Category: Healthcare Delivery: 2 to 4 HoursThe Diagnostic Specialty Antibodies Market is expected to grow at a CAGR of 4.6% from 2022–2029 to reach $39.99 billion by 2029. Antibodies are used for therapeutic and diagnostic purposes. In diagnosis procedures, the sample containing antigens binds to the antibodies and assists in the diagnosis procedure. Diagnostic antibodies are used in the diagnosis of both infectious and chronic diseases. It is widely used in diagnosing cancer and infectious diseases. Additionally, it is used in pregnancy detection and for monitoring drug action in the body.
The increasing incidences of infectious diseases, cancer, autoimmune diseases, and pregnancy, the availability of funding for diagnosis of various diseases by different organizations, increasing number of fundings for clinical trials involving the use of diagnostic antibodies, and product approvals of test kits containing diagnostic antibodies are factors driving the growth of this market.
In addition, the high prevalence of diseases in emerging countries and the initiatives by the public and private organizations for improving the diagnosis activities for eradicating infectious diseases are expected to offer significant opportunities for the growth of this market.
Click here to: Get Free Request Sample Copy of this report
COVID-19 Impact Assessment
The outbreak of the COVID-19 pandemic impacted the diagnostic specialty antibodies market both positively and negatively. The surge in COVID-19 cases increased the demand for point-of-care test kits containing antibodies due to their capability to provide faster results than other testing methods. To perform mass testing, public organizations in various countries purchased a considerable number of test kits. For instance, the WHO in September 2020, partnered with Africa Centers for Disease Control and Prevention (Africa CDC), Access to covid-19 Tools (ACT) Accelerator, the Clinton Health Access Initiative (CHAI), the Bill & Melinda Gates Foundation, the Foundation for Innovative New Diagnostics (FIND), the Global Fund, and UNITAID for providing COVID-19 antigen test kits to the low and middle-income countries.
Similarly, the European Commission in December 2020 signed an agreement with F. Hoffmann-La Roche AG (Switzerland) and Abbott Laboratories (U.S.) for purchasing 20 million rapid antigen tests for mass testing the EU Member States. The expected third wave of COVID-19 is further expected to increase the demand for antibody-based testing in the future.
The number of unintended pregnancies increased significantly worldwide due to the disruptions caused by the COVID-19 pandemic. The UN Population Fund on 11th March 2021 reported that around 12 million women did not have access to contraceptives during the pandemic due to mobility restrictions, supply chain disruptions, and the reluctance of people to visit hospitals and clinics in fear of developing an infection. The UN Population Fund stated that this problem is expected to cause 1.4 million unintended pregnancies in 2021 globally.
Regulatory authorities worldwide are actively providing approval to antibody-based test kits to support the mass screening across countries. These initiatives are further expected to have a positive impact on the market.
However, the temporary supply chain disruption due to nationwide lockdowns led to the shortage of test kits across numerous countries; thus, such disruptions hindered the growth of this market to a notable extent.
Public and Private Organization Initiatives to Eradicate Infectious Diseases is Projected to Drive the Adoption of Diagnostic Antibody
Various organizations are actively involved in eradicating infectious diseases by improving diagnostic testing; this initiative is expected to drive the adoption of diagnostic antibodies for testing.
Some of the notable initiatives for disease eradication are given below:
- The U.S. government, in the Fiscal Year 2021, funded $332 million for the TB control programs globally. The funding was used in more than 50 countries, including 20 of the 30 high burden countries. This funding is used for the prevention, detection, treatment, and R&D of TB.
- In 2021, the European Commission announced the ‘Europe’s Beating Cancer Plan.’ The plan included four key action areas. One of the key areas was early detection of cancer by improving access to better diagnostics and supporting the member states by ensuring that 90% of the EU population who are expected to have breast, cervical, and colorectal cancer are provided better services in diagnosis by 2025.
- In 2020, the CDC announced the strategic plan to eradicate hepatitis in the U.S. till 2030. The plan was aimed at developing and promoting hepatitis testing in the country.
- The U.S. Department of Health and Human Services (HHS), in 2019, announced the ‘Ending the HIV Epidemic in the U.S.’ plan. This initiative was aimed at eradicating HIV disease in the U.S. by 2030. This plan was launched to improve HIV prevention, diagnosis, and treatments.
Growing Prevalence of Diseases in Emerging Countries to Positively Impact Market
The high burden of diseases in emerging countries is expected to increase the demand for antibody-based test kits. According to the Cancer Tomorrow estimates, the number of cancer cases in China was estimated to be 4.57 million in 2020, and this number is projected to rise to 6.85 million in 2040. Similarly, the number of cancer cases in Brazil was estimated to rise to 995,000 by 2040 from 592,000 in 2020.
Furthermore, the International Diabetes Federation (IDF) estimated that in Mexico, 12.8 million cases of diabetes were reported in 2019, and this number is expected to increase to 22.3 million by 2045. Thus, the high prevalence of diseases is expected to increase the number of testing and positively impact market growth.
Key Findings in the Global Diagnostic Specialty Antibodies Market Study:
The Primary Antibody Segment Estimated to Generate Larger Proportion of Revenue in 2022
Primary antibodies are highly preferred over secondary antibodies due to their capability to directly bind with the targeted antigen. In addition, primary antibodies can recognize post-translational modifications (PTMs), such as glycosylation, phosphorylation, methylation, or acetylation. Furthermore, primary antibodies are mandatorily used in almost all assays. Hence, these factors attribute to the large market share of this segment.
Recombinant Antibody Segment Projected to Grow at Fastest CAGR During Forecast Period
Recombinant antibodies are more cost-effective than monoclonal antibodies and have a better affinity for binding to the target antigen. Also, recombinant monoclonal antibodies are produced in a shorter duration than other clonal antibodies. Hence, these factors drive its demand in the market.
ELISA Segment Expected to Account for the Largest Share in 2022
ELISA has a higher specificity, efficiency, and sensitivity and is relatively simple compared to western blot and other assays. These are the key factors promoting the demand for the ELISA technique. In addition, this test is also more cost-effective than IHC, western blot, and other assays, which further drives its demand in the market.
Unconjugated Antibodies Segment Expected to Grow at Fastest CAGR During Forecast Period
The specificity and sensitivity of unconjugated antibody is the prime factor driving its demand in the market. Furthermore, the demand for unconjugated antibodies for developing secondary antibody conjugates contributes to the growth of this segment.
Infectious Diseases Segment Expected to Account for Largest Share in 2022
The growth of the infectious diseases segment is attributed to the rising incidences of infectious diseases globally, resulting in the demand for diagnostic testing. The growing trend of self-testing kits and the increasing number of regulatory approvals of test kits for infectious diseases testing further contribute to the growth of this segment.
Asia-Pacific: Fastest growing regional market
The high market growth rate is attributed to the rising prevalence of diseases and the increasing incidences of unintended pregnancies in the region. In addition, factors such as funding availability for improving diagnosis and the rising number of government initiatives to eradicate infectious diseases, developments in the market, including product approvals and distribution agreements for antibody-based test kits, have further boosted the growth of this market in the region.
Key Players
The report includes a competitive landscape based on an extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past three years. The key players profiled in the global diagnostic specialty antibodies market report are Abcam plc (U.K.), F. Hoffman La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Creative Diagnostics (U.S.), Merck KGaA (Germany), Agilent Technologies, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Rockland Immunochemicals, Inc. (U.S.), Santa Cruz Biotechnology (U.S.), Novus Biologicals, LLC (U.S.), and Thermo Fisher Scientific Inc. (U.S.).
Scope of the Report:
Diagnostic Specialty Antibodies Market, by Type
- Primary Antibodies
- Secondary Antibodies
Diagnostic Specialty Antibodies Market, by Clonality
- Monoclonal Antibodies
- Polyclonal Antibodies
- Recombinant Antibodies
Diagnostic Specialty Antibodies Market, by Technique
- ELISA
- Lateral Flow Assay
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
- Immunocytochemistry (ICC)
- Other Techniques
(Other techniques include immunofluorescence, flow cytometry, in situ hybridization, dot blot, radioimmunoassay, and others)
Diagnostic Specialty Antibodies Market, by Conjugate
- Conjugated Antibodies
- Unconjugated Antibodies
Diagnostic Specialty Antibodies Market, by Application
- Infectious Diseases
- Respiratory Infections
- COVID-19
- Influenza
- Tuberculosis (TB)
- Pneumonia
- Other Respiratory Infections
(Other respiratory infections include strep infections, pertussis, and respiratory syncytial virus (RSV), among others)
- Parasitic Infections
- Dengue
- Malaria
- Other Parasitic Infections
(Other parasitic infections include leishmaniasis and zika, among others)
- Gastrointestinal Infections (GI Infections)
- Salmonellosis
- Coli Infections
- Other GI Infections
(Other GI infections include cholera, Helicobacter pylori (H. pylori), and campylobacteriosis, among others)
- Blood Borne Diseases
- Hepatitis
- HIV
- Other Blood-Borne Infections
(Other blood-borne infections include syphilis, chlamydia, and gonorrhea, among others)
- Other Infectious Diseases
(Other infectious diseases include sepsis, rubella, impetigo, and others)
- Respiratory Infections
- Oncology
- Pregnancy Detection/Fertility Testing
- Other Applications
(Other applications include Alzheimer’s, autoimmune diseases and cardiac diseases, diabetes, and others)
Diagnostic Specialty Antibodies Market, by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- China
- Japan
- India
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa
Key questions answered in the report:
This study offers a detailed assessment of the diagnostic specialty antibodies market, including the market sizes and forecasts of the diagnostic specialty antibodies market segmented based on type, clonality, technique, conjugate, and application. The diagnostic specialty antibodies market studied in this report also involves the value analysis of various segments and subsegments of diagnostic specialty antibodies at the regional and country levels.
The global diagnostic specialty antibodies market is projected to reach $39.99 billion by 2029, at a CAGR of 4.6% during the forecast period.
Based on type, the primary antibody segment is estimated to hold the largest share in 2022. The largest share is attributed to the high preference of primary antibodies in diagnosis assays over secondary antibodies due to their capability to directly bind to the targeted antigen. In addition, the regulatory approvals of primary antibody-based kits further increase the growth of this segment.
The recombinant segment is estimated to grow at the fastest CAGR during the forecast period. Recombinant antibodies are more cost-effective than monoclonal antibodies and have a better affinity for binding to the target antigen. In addition, recombinant monoclonal antibodies are produced in a shorter duration and have higher reproducibility over other clonal antibodies. These factors contribute to its demand in the market.
The growth of this market is mainly attributed to the growing prevalence of diseases worldwide and their burden on the economy, the increasing usage of diagnostic antibodies in research studies, the availability of funding for research, the increasing number of regulatory approvals of diagnostic test kits containing antibodies, and the rising incidences of unintended pregnancies worldwide. In addition, the initiatives taken by numerous public and private organizations to enhance diagnostic testing to eradicate infectious diseases and the growing incidences of diseases in emerging countries are expected to offer significant growth opportunities to the existing market players and new entrants in the global diagnostic specialty antibodies market.
The key players operating in the global diagnostic specialty antibodies market include Abcam plc (U.K.), F. Hoffman La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Creative Diagnostics (U.S.), Merck KGaA (Germany), Agilent Technologies, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Rockland Immunochemicals, Inc. (U.S.), Santa Cruz Biotechnology (U.S.), Novus Biologicals, LLC (U.S.), and Thermo Fisher Scientific Inc . (U.S.).
Emerging economies from Asia, such as China and India, are projected to offer significant growth opportunities for the players operating in this market due to the growing prevalence of diseases in these countries and their high economic burden on the people, the increasing number of fundings and investments for diagnostic activities, and the high incidences of unintended pregnancies.
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for this Study
2.5. Limitations for the Study
3. Executive Summary
4. Market Insights
4.1. Introduction
4.2. Drivers
4.2.1. High Burden of Infectious and Chronic Diseases Globally
4.2.2. Increasing Funding for Clinical Trials and Research
4.2.3. Increasing Use of Immunoassays in Oncology
4.2.4. Technological Advancements in Immunoassays
4.2.5. Growing Demand for Pregnancy Testing Owing to Self-testing and Restricted Use of Contraceptives
4.3. Restraints
4.3.1. Use of Substitute Tests for Diagnosis
4.3.2. The Availability of Vaccines for Diseases Like Hepatitis, Tuberculosis, Influenza, Malaria, and Dengue
4.4. Opportunities
4.4.1. Initiatives by Public and Private Organizations to Increase Diagnostic Testing
4.4.2. Emerging Economies
4.5. Challenges
4.5.1. Misleading Results With Antibody Tests
4.5.2. High Cost of Manufacturing Antibodies
4.6. Impact of COVID-19 on the Diagnostic Specialty Antibodies Market
5. Global Diagnostic Specialty Antibodies Market, by Type
5.1. Introduction
5.2. Primary Antibodies
5.3. Secondary Antibodies
6. Global Diagnostic Specialty Antibodies Market, by Clonality
6.1. Introduction
6.2. Monoclonal Antibodies
6.3. Polyclonal Antibodies
6.4. Recombinant Antibodies
7. Global Diagnostic Specialty Antibodies Market, by Application
7.1. Introduction
7.2. Infectious Diseases
7.2.1. Respiratory Infections
7.2.1.1. COVID-19
7.2.1.2. Pneumonia
7.2.1.3. Influenza
7.2.1.4. Tuberculosis (TB)
7.2.1.5. Other Respiratory Infections
7.2.2. Parasitic Infections
7.2.2.1. Dengue
7.2.2.2. Malaria
7.2.2.3. Other Parasitic Infections
7.2.3. Gastrointestinal (GI) Infections
7.2.3.1. Salmonellosis
7.2.3.2. E. coli Infections
7.2.3.3. Other GI Infections
7.2.4. Blood-borne Infections
7.2.4.1. Hepatitis
7.2.4.2. HIV
7.2.4.3. Other Blood-borne Infections
7.2.5. Other Infectious Diseases
7.3. Oncology
7.4. Pregnancy Detection/Fertility Testing
7.5. Cardiac Marker Testing
7.6. Other Applications
8. Global Diagnostic Specialty Antibodies Market, by Technique
8.1. Introduction
8.2. ELISA
8.3. Lateral Flow Assay
8.4. Immunohistochemistry (IHC)
8.5. Immunoprecipitation (IP)
8.6. Western Blot (WB)
8.7. Immunocytochemistry (ICC)
8.8. Other Techniques
9. Global Diagnostic Specialty Antibodies Market, by Conjugate
9.1. Introduction
9.2. Unconjugated Antibodies
9.3. Conjugated Antibodies
10. Diagnostic Specialty Antibodies Market, by Geography
10.1. Introduction
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. France
10.3.3. U.K.
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe (RoE)
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Rest of Asia-Pacific (RoAPAC)
10.5. Latin America
10.6. Middle East & Africa
11. Competitive Landscape
11.1. Introduction
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Market Share Analysis (2020)
11.4.1. F. Hoffmann-La Roche
11.4.2. Thermo Fisher Scientific, Inc.
11.4.3. Merck KGaA
12. Company Profiles
12.1. Abcam Plc
12.1.1. Business Overview
12.1.2. Financial Overview
12.1.3. Product Benchmarking
12.1.4. Strategic Developments
12.2. F. Hoffmann-La Roche Ltd
12.2.1. Business Overview
12.2.2. Financial Overview
12.2.3. Product Portfolio
12.3. Bio-Rad Laboratories, Inc.
12.3.1. Business Overview
12.3.2. Financial Overview
12.3.3. Product Portfolio
12.3.4. Strategic Developments
12.4. Creative Diagnostics
12.4.1. Business Overview
12.4.2. Product Portfolio
12.4.3. Strategic Developments
12.5. Merck KGaA
12.5.1. Business Overview
12.5.2. Financial Overview
12.5.3. Product Portfolio
12.6. Agilent Technologies, Inc.
12.6.1. Business Overview
12.6.2. Financial Overview
12.6.3. Product Portfolio
12.6.4. Strategic Developments
12.7. Becton, Dickinson and Company
12.7.1. Business Overview
12.7.2. Financial Overview
12.7.3. Product Portfolio
12.8. Rockland Immunochemicals, Inc
12.8.1. Business Overview
12.8.2. Product Portfolio
12.8.3. Strategic Developments
12.9. Santa Cruz Biotechnology, Inc
12.9.1. Business Overview
12.9.2. Product Portfolio
12.10. Novus Biologicals, Llc
12.10.1. Business Overview
12.10.2. Financial Overview
12.10.3. Product Portfolio
12.11. Thermo Fisher Scientific Inc.
12.11.1. Business Overview
12.11.2. Financial Overview
12.11.3. Product Portfolio
13. Appendix
13.1. Questionnaire
13.2. Available Customization
List of Tables
Table 1 Global Diagnostic Specialty Antibodies Market Drivers: Impact Analysis (2022–2029)
Table 2 Research Funding
Table 3 Cancer Biomarkers for Immunoassay
Table 4 Global Diagnostic Specialty Antibodies Market Restraints: Impact Analysis (2022–2029)
Table 5 Recent Initiatives for Improving Diseases Diagnosis
Table 6 Recent COVID-19 Test Kit Approvals
Table 7 Global Diagnostic Specialty Antibodies Market Size, by Type, 2020–2029 (USD Million)
Table 8 Global Primary Diagnostic Specialty Antibodies Market Size, by Country/Region, 2020–2029 (USD Million)
Table 9 Global Secondary Diagnostic Specialty Antibodies Market Size, by Country/Region, 2020–2029 (USD Million)
Table 10 Global Diagnostic Specialty Antibodies Market Size, by Clonality, 2020–2029 (USD Million)
Table 11 Global Diagnostic Monoclonal Antibodies Market, by Country/Region, 2020–2029 (USD Million)
Table 12 Global Diagnostic Polyclonal Antibodies Market Size, by Country/Region, 2020–2029 (USD Million)
Table 13 Global Diagnostic Recombinant Antibodies Market Size, by Country/Region, 2020–2029 (USD Million)
Table 14 Global Diagnostic Specialty Antibodies Market Size, by Application, 2020–2029 (USD Million)
Table 15 Global Diagnostic Specialty Antibodies Market Size for Infectious Diseases, by Type, 2020–2029 (USD Million)
Table 16 Global Diagnostic Specialty Antibodies Market Size for Infectious Diseases, By Country/Region, 2020–2029 (USD Million)
Table 17 Global Diagnostic Specialty Antibodies Market Size for Respiratory Infections, by Type, 2020–2029 (USD Million)
Table 18 Global Diagnostic Specialty Antibodies Market Size for Respiratory Infections, By Country/ Region, 2020–2029 (USD Million)
Table 19 COVID-19 Testing by Country
Table 20 List of Emergency Use Authorizations (EUA) From The U.S. FDA for Test Kits Containing Antibodies
Table 21 List of Product Launches of Antibodies-based Test Kits
Table 22 List of Product Launches of Test Kits for Specific Country
Table 23 Global Diagnostic Specialty Antibodies Market Size for COVID-19, by Country/Region, 2020–2029 (USD Million)
Table 24 Global Diagnostic Specialty Antibodies Market Size for Pneumonia, by Country/Region, 2020–2029 (USD Million)
Table 25 Global Diagnostic Specialty Antibodies Market Size for Influenza, by Country/Region, 2020–2029 (USD Million)
Table 26 Global Diagnostic Specialty Antibodies Market Size for Tuberculosis, by Country/Region, 2020–2029 (USD Million)
Table 27 Global Diagnostic Specialty Antibodies Market Size for Other Respiratory Infections, By Country/Region, 2020–2029 (USD Million)
Table 28 Global Diagnostic Specialty Antibodies Market Size for Parasitic Infections, by Type, 2020–2029 (USD Million)
Table 29 Global Diagnostic Specialty Antibodies Market Size for Parasitic Infections, By Country/Region, 2020–2029 (USD Million)
Table 30 Global Diagnostic Specialty Antibodies Market Size for Dengue by Country/Region, 2020–2029 (USD Million)
Table 31 Global Diagnostic Specialty Antibodies Market Size for Malaria by Country/Region, 2020–2029 (USD Million)
Table 32 Global Diagnostic Specialty Antibodies Market Size for Other Parasitic Infections, By Country/Region, 2020–2029 (USD Million)
Table 33 Global Diagnostic Specialty Antibodies Market Size for GI Infections, by Type, 2020–2029 (USD Million)
Table 34 Global Diagnostic Specialty Antibodies Market Size for GI Infections, by Country/Region, 2020–2029 (USD Million)
Table 35 Global Diagnostic Specialty Antibodies Market Size for Salmonellosis, by Country/ Region, 2020–2029 (USD Million)
Table 36 Global Diagnostic Specialty Antibodies Market Size for E. coli Infections, by Country/ Region, 2020–2029 (USD Million)
Table 37 Global Diagnostic Specialty Antibodies Market Size for Other GI Infections, by Country/ Region, 2020–2029 (USD Million)
Table 38 Global Diagnostic Specialty Antibodies Market Size for Blood-borne Infections, by Type, 2020–2029 (USD Million)
Table 39 Global Diagnostic Specialty Antibodies Market Size for Blood-borne InfectionsBy Country/Region, 2020–2029 (USD Million)
Table 40 Global Diagnostic Specialty Antibodies Market Size for Hepatitis, by Country/Region, 2020–2029 (USD Million)
Table 41 Global Diagnostic Specialty Antibodies Market Size for HIV , by Country/Region, 2020–2029 (USD Million)
Table 42 Global Diagnostic Specialty Antibodies Market Size for Other Blood-borne Infections , By Country/Region, 2020–2029 (USD Million)
Table 43 Global Diagnostic Specialty Antibodies Market Size for Other Infectious Diseases By Country/Region, 2020–2029 (USD Million)
Table 44 Global Diagnostic Specialty Antibodies Market Size for Oncology, by Country/Region, 2020–2029 (USD Million)
Table 45 Estimated Number of Births in 2020
Table 46 Global Diagnostic Specialty Antibodies Market Size for Pregnancy Detection/Fertility Testing, by Country/Region, 2020–2029 (USD Million)
Table 47 Global Diagnostic Specialty Antibodies Market Size for Cardiac Marker Testing, By Country/Region, 2020–2029 (USD Million)
Table 48 Global Diagnostic Specialty Antibodies Market Size for Other Applications, By Country/Region, 2020–2029 (USD Million)
Table 49 Global Diagnostic Specialty Antibodies Market Size, by Technique, 2020–2029 (USD Million)
Table 50 Global Diagnostic Specialty Antibodies Market Size for ELISA, by Country/Region, 2020–2029 (USD Million)
Table 51 Global Diagnostic Specialty Antibodies Market Size for Lateral Flow Assay, By Country/Region, 2020–2029 (USD Million)
Table 52 Global Diagnostic Specialty Antibodies Market Size for Immunohistochemistry, By Country/Region, 2020–2029 (USD Million)
Table 53 Global Diagnostic Specialty Antibodies Market Size for Immunoprecipitation, By Country/Region, 2020–2029 (USD Million)
Table 54 Global Diagnostic Specialty Antibodies Market Size for Western Blot, by Country/Region, 2020–2029 (USD Million)
Table 55 Global Diagnostic Specialty Antibodies Market Size Immunocytochemistry, By Country/Region, 2020–2029 (USD Million)
Table 56 Global Diagnostic Specialty Antibodies Market Size for Other Techniques, By Country/Region, 2020–2029 (USD Million)
Table 57 Global Diagnostic Specialty Antibodies Market Size, by Conjugate, 2020–2029 (USD Million)
Table 58 Global Unconjugated Diagnostic Specialty Antibodies Market, by Country/Region, 2020–2029 (USD Million)
Table 59 Global Conjugated Diagnostic Specialty Antibodies Market Size, by Country/Region, 2020–2029 (USD Million)
Table 60 Global Diagnostic Specialty Antibodies Market Size, by Country/Region, 2020–2029 (USD Million)
Table 61 North America: Diagnostic Specialty Antibodies Market Size, by Country, 2020–2029 (USD Million)
Table 62 North America: Diagnostic Specialty Antibodies Market Size, by Type, 2020–2029 (USD Million)
Table 63 North America: Diagnostic Specialty Antibodies Market Size, by Clonality, 2020–2029 (USD Million)
Table 64 North America: Diagnostic Specialty Antibodies Market Size, by Technique, 2020–2029 (USD Million)
Table 65 North America: Diagnostic Specialty Antibodies Market Size, by Conjugate, 2020–2029 (USD Million)
Table 66 North America: Diagnostic Specialty Antibodies Market Size, by Application, 2020–2029 (USD Million)
Table 67 North America: Diagnostic Specialty Antibodies Market Size for Infectious Diseases, By Type, 2020–2029 (USD Million)
Table 68 North America: Diagnostic Specialty Antibodies Market Size for Respiratory Infections, By Type, 2020–2029 (USD Million)
Table 69 North America: Diagnostic Specialty Antibodies Market Size for Parasitic Infections, by Type, 2020–2029 (USD Million)
Table 70 North America: Diagnostic Specialty Antibodies Market Size for GI Infections, by Type, 2020–2029 (USD Million)
Table 71 North America: Diagnostic Specialty Antibodies Market Size for Blood-borne Infections, By Type, 2020–2029 (USD Million)
Table 72 List of Products Received Emergency Use Authorization From U.S. FDA
Table 73 Funding Provided by The National Cancer Institute for Researchers in 2018 By Disease Areas
Table 74 List of Antibodies Launched for Diagnostic Purposes in the U.S
Table 75 U.S.: Diagnostic Specialty Antibodies Market Size, by Type, 2020–2029 (USD Million)
Table 76 U.S.: Diagnostic Specialty Antibodies Market Size, by Clonality, 2020–2029 (USD Million)
Table 77 U.S.: Diagnostic Specialty Antibodies Market Size, by Technique, 2020–2029 (USD Million)
Table 78 U.S.: Diagnostic Specialty Antibodies Market Size, by Conjugate, 2020–2029 (USD Million)
Table 79 U.S.: Diagnostic Specialty Antibodies Market Size, by Application, 2020–2029 (USD Million)
Table 80 U.S.: Diagnostic Specialty Antibodies Market Size for Infectious Diseases, by Type, 2020–2029 (USD Million)
Table 81 U.S.: Diagnostic Specialty Antibodies Market Size for Respiratory Infections, by Type, 2020–2029 (USD Million)
Table 82 U.S.: Diagnostic Specialty Antibodies Market Size for Parasitic Infections, by Type, 2020–2029 (USD Million)
Table 83 U.S.: Diagnostic Specialty Antibodies Market Size for GI Infections, by Type, 2020–2029 (USD Million)
Table 84 U.S.: Diagnostic Specialty Antibodies Market Size for Blood-borne Infections, by Type, 2020–2029 (USD Million)
Table 85 Recent Health Canada Approvals for SARS-CoV-2 Test Kits (2020–2021)
Table 86 Canada: Diagnostic Specialty Antibodies Market Size, by Type, 2020–2029 (USD Million)
Table 87 Canada: Diagnostic Specialty Antibodies Market Size, by Clonality, 2020–2029 (USD Million)
Table 88 Canada: Diagnostic Specialty Antibodies Market Size, by Technique, 2020–2029 (USD Million)
Table 89 Canada: Diagnostic Specialty Antibodies Market Size, by Conjugate, 2020–2029 (USD Million)
Table 90 Canada: Diagnostic Specialty Antibodies Market Size, by Application, 2020–2029 (USD Million)
Table 91 Canada: Diagnostic Specialty Antibodies Market Size for Infectious Diseases, by Type, 2020–2029 (USD Million)
Table 92 Canada: Diagnostic Specialty Antibodies Market Size for Respiratory Infections, by Type, 2020–2029 (USD Million)
Table 93 Canada: Diagnostic Specialty Antibodies Market Size for Parasitic Infections, by Type, 2020–2029 (USD Million)
Table 94 Canada: Diagnostic Specialty Antibodies Market Size for GI Infections, by Type, 2020–2029 (USD Million)
Table 95 Canada: Diagnostic Specialty Antibodies Market Size for Blood-borne Infections, by Type, 2020–2029 (USD Million)
Table 96 Europe: Diagnostic Specialty Antibodies Market Size, by Country, 2020–2029 (USD Million)
Table 97 Europe: Diagnostic Specialty Antibodies Market Size, by Type, 2020–2029 (USD Million)
Table 98 Europe: Diagnostic Specialty Antibodies Market Size, by Clonality, 2020–2029 (USD Million)
Table 99 Europe: Diagnostic Specialty Antibodies Market Size, by Technique, 2020–2029 (USD Million)
Table 100 Europe: Diagnostic Specialty Antibodies Market Size, by Conjugate, 2020–2029 (USD Million)
Table 101 Europe: Diagnostic Specialty Antibodies Market Size, by Application, 2020–2029 (USD Million)
Table 102 Europe: Diagnostic Specialty Antibodies Market Size for Infectious Diseases, by Type, 2020–2029 (USD Million)
Table 103 Europe: Diagnostic Specialty Antibodies Market Size for Respiratory Infections, by Type, 2020–2029 (USD Million)
Table 104 Europe: Diagnostic Specialty Antibodies Market Size for Parasitic Infections, by Type, 2020–2029 (USD Million)
Table 105 Europe: Diagnostic Specialty Antibodies Market Size for GI Infections, by Type, 2020–2029 (USD Million)
Table 106 Europe: Diagnostic Specialty Antibodies Market Size for Blood-borne Infections, by Type, 2020–2029 (USD Million)
Table 107 Germany: Diagnostic Specialty Antibodies Market Size, by Type, 2020–2029 (USD Million)
Table 108 Germany: Diagnostic Specialty Antibodies Market Size, by Clonality, 2020–2029 (USD Million)
Table 109 Germany: Diagnostic Specialty Antibodies Market Size, by Technique, 2020–2029 (USD Million)
Table 110 Germany: Diagnostic Specialty Antibodies Market Size, by Conjugate, 2020–2029 (USD Million)
Table 111 Germany: Diagnostic Specialty Antibodies Market Size, by Application, 2020–2029 (USD Million)
Table 112 Germany: Diagnostic Specialty Antibodies Market Size for Infectious Diseases, by Type, 2020–2029 (USD Million)
Table 113 Germany: Diagnostic Specialty Antibodies Market Size for Respiratory Infections, by Type, 2020–2029 (USD Million)
Table 114 Germany: Diagnostic Specialty Antibodies Market Size for Parasitic Infections, by Type, 2020–2029 (USD Million)
Table 115 Germany: Diagnostic Specialty Antibodies Market Size for GI Infections, by Type, 2020–2029 (USD Million)
Table 116 Germany: Diagnostic Specialty Antibodies Market Size for Blood-borne Infections, by Type, 2020–2029 (USD Million)
Table 117 France: Diagnostic Specialty Antibodies Market Size, by Type, 2020–2029 (USD Million)
Table 118 France: Diagnostic Specialty Antibodies Market Size, by Clonality, 2020–2029 (USD Million)
Table 119 France: Diagnostic Specialty Antibodies Market Size, by Technique, 2020–2029 (USD Million)
Table 120 France: Diagnostic Specialty Antibodies Market Size, by Conjugate, 2020–2029 (USD Million)
Table 121 France: Diagnostic Specialty Antibodies Market Size, by Application, 2020–2029 (USD Million)
Table 122 France: Diagnostic Specialty Antibodies Market Size, by Type, 2020–2029 (USD Million)
Table 123 France: Diagnostic Specialty Antibodies Market Size for Respiratory Infections, by Type, 2020–2029 (USD Million)
Table 124 France: Diagnostic Specialty Antibodies Market Size for Parasitic Infections, by Type, 2020–2029 (USD Million)
Table 125 France: Diagnostic Specialty Antibodies Market Size for GI Infections, by Type, 2020–2029 (USD Million)
Table 126 France: Diagnostic Specialty Antibodies Market Size for Blood-borne Infections, by Type, 2020–2029 (USD Million)
Table 127 U.K.: Diagnostic Specialty Antibodies Market Size, by Type, 2020–2029 (USD Million)
Table 128 U.K.: Diagnostic Specialty Antibodies Market Size, by Clonality, 2020–2029 (USD Million)
Table 129 U.K.: Diagnostic Specialty Antibodies Market Size, by Technique, 2020–2029 (USD Million)
Table 130 U.K.: Diagnostic Specialty Antibodies Market Size, by Conjugate, 2020–2029 (USD Million)
Table 131 U.K.: Diagnostic Specialty Antibodies Market Size, by Application, 2020–2029 (USD Million)
Table 132 U.K.: Diagnostic Specialty Antibodies Market Size for Infectious Diseases, by Type, 2020–2029 (USD Million)
Table 133 U.K.: Diagnostic Specialty Antibodies Market Size for Respiratory Infections, by Type, 2020–2029 (USD Million)
Table 134 U.K.: Diagnostic Specialty Antibodies Market Size for Parasitic Infections, by Type, 2020–2029 (USD Million)
Table 135 U.K.: Diagnostic Specialty Antibodies Market Size for GI Infections, by Type, 2020–2029 (USD Million)
Table 136 U.K.: Diagnostic Specialty Antibodies Market Size for Blood-borne Infections, by Type, 2020–2029 (USD Million)
Table 137 Italy: Diagnostic Specialty Antibodies Market Size, by Type, 2020–2029 (USD Million)
Table 138 Italy: Diagnostic Specialty Antibodies Market Size, by Clonality, 2020–2029 (USD Million)
Table 139 Italy: Diagnostic Specialty Antibodies Market Size, by Technique, 2020–2029 (USD Million)
Table 140 Italy: Diagnostic Specialty Antibodies Market Size, by Conjugate, 2020–2029 (USD Million)
Table 141 Italy: Diagnostic Specialty Antibodies Market Size, by Application, 2020–2029 (USD Million)
Table 142 Italy: Diagnostic Specialty Antibodies Market Size for Infectious Diseases, by Type, 2020–2029 (USD Million)
Table 143 Italy: Diagnostic Specialty Antibodies Market Size for Parasitic Infections, by Type, 2020–2029 (USD Million)
Table 144 Italy: Diagnostic Specialty Antibodies Market Size for Respiratory Infections, by Type, 2020–2029 (USD Million)
Table 145 Italy: Diagnostic Specialty Antibodies Market Size for GI Infections, by Type, 2020–2029 (USD Million)
Table 146 Italy: Diagnostic Specialty Antibodies Market Size for Blood-borne Infections, by Type, 2020–2029 (USD Million)
Table 147 Spain: Diagnostic Specialty Antibodies Market Size, by Type, 2020–2029 (USD Million)
Table 148 Spain: Diagnostic Specialty Antibodies Market Size, by Clonality, 2020–2029 (USD Million)
Table 149 Spain: Diagnostic Specialty Antibodies Market Size, by Technique, 2020–2029 (USD Million)
Table 150 Spain: Diagnostic Specialty Antibodies Market Size, by Conjugate, 2020–2029 (USD Million)
Table 151 Spain: Diagnostic Specialty Antibodies Market Size, by Application, 2020–2029 (USD Million)
Table 152 Spain: Diagnostic Specialty Antibodies Market Size for Infectious Diseases, by Type, 2020–2029 (USD Million)
Table 153 Spain: Diagnostic Specialty Antibodies Market Size for Respiratory Infections, by Type, 2020–2029 (USD Million)
Table 154 Spain: Diagnostic Specialty Antibodies Market Size for Parasitic Infections, by Type, 2020–2029 (USD Million)
Table 155 Spain: Diagnostic Specialty Antibodies Market Size for GI Infections, by Type, 2020–2029 (USD Million)
Table 156 Spain: Diagnostic Specialty Antibodies Market Size for Blood-borne Infections, by Type, 2020–2029 (USD Million)
Table 157 Incidence of COVID-19 in RoE Countries (Cases As of 21st December 2021)
Table 158 Healthcare Expenditure % Contribution to GDP
Table 159 Rest of Europe: Diagnostic Specialty Antibodies Market Size, by Type, 2020–2029 (USD Million)
Table 160 Rest of Europe: Diagnostic Specialty Antibodies Market Size, by Clonality, 2020–2029 (USD Million)
Table 161 Rest of Europe: Diagnostic Specialty Antibodies Market Size, by Technique, 2020–2029 (USD Million)
Table 162 Rest of Europe: Diagnostic Specialty Antibodies Market Size, by Conjugate, 2020–2029 (USD Million)
Table 163 Rest of Europe: Diagnostic Specialty Antibodies Market Size, by Application, 2020–2029 (USD Million)
Table 164 Rest of Europe: Diagnostic Specialty Antibodies Market Size for Infectious Diseases, by Type, 2020–2029 (USD Million)
Table 165 Rest of Europe: Diagnostic Specialty Antibodies Market Size for Respiratory Infections, By Type, 2020–2029 (USD Million)
Table 166 Rest of Europe: Diagnostic Specialty Antibodies Market Size for Parasitic Infections, by Type, 2020–2029 (USD Million)
Table 167 Rest of Europe: Diagnostic Specialty Antibodies Market Size for GI Infections, by Type, 2020–2029 (USD Million)
Table 168 Rest of Europe: Diagnostic Specialty Antibodies Market Size for Blood-borne Infections, By Type, 2020–2029 (USD Million)
Table 169 Asia-Pacific: Diagnostic Specialty Antibodies Market Size, by Country, 2020–2029 (USD Million)
Table 170 Asia-Pacific: Diagnostic Specialty Antibodies Market Size, by Type, 2020–2029 (USD Million)
Table 171 Asia-Pacific: Diagnostic Specialty Antibodies Market Size, by Clonality, 2020–2029 (USD Million)
Table 172 Asia-Pacific: Diagnostic Specialty Antibodies Market Size, by Technique, 2020–2029 (USD Million)
Table 173 Asia-Pacific: Diagnostic Specialty Antibodies Market Size, by Conjugate, 2020–2029 (USD Million)
Table 174 Asia-Pacific: Diagnostic Specialty Antibodies Market Size, by Application, 2020–2029 (USD Million)
Table 175 Asia-Pacific: Diagnostic Specialty Antibodies Market Size for Infectious Diseases, by Type, 2020–2029 (USD Million)
Table 176 Asia-Pacific: Diagnostic Specialty Antibodies Market Size for Respiratory Infections, by Type, 2020–2029 (USD Million)
Table 177 Asia-Pacific: Diagnostic Specialty Antibodies Market Size for Parasitic Infections, by Type, 2020–2029 (USD Million)
Table 178 Asia-Pacific: Diagnostic Specialty Antibodies Market Size for GI Infections, by Type, 2020–2029 (USD Million)
Table 179 Asia-Pacific: Diagnostic Specialty Antibodies Market Size for Blood-borne Infections, By Type, 2020–2029 (USD Million)
Table 180 China: Diagnostic Specialty Antibodies Market Size, by Type, 2020–2029 (USD Million)
Table 181 China: Diagnostic Specialty Antibodies Market Size, by Clonality, 2020–2029 (USD Million)
Table 182 China: Diagnostic Specialty Antibodies Market Size, by Technique, 2020–2029 (USD Million)
Table 183 China: Diagnostic Specialty Antibodies Market Size, by Conjugate, 2020–2029 (USD Million)
Table 184 China: Diagnostic Specialty Antibodies Market Size, by Application, 2020–2029 (USD Million)
Table 185 China: Diagnostic Specialty Antibodies Market Size for Infectious Diseases, by Type, 2020–2029 (USD Million)
Table 186 China: Diagnostic Specialty Antibodies Market Size for Respiratory Infections, by Type, 2020–2029 (USD Million)
Table 187 China: Diagnostic Specialty Antibodies Market Size for Parasitic Infections, by Type, 2020–2029 (USD Million)
Table 188 China: Diagnostic Specialty Antibodies Market Size for GI Infections, by Type, 2020–2029 (USD Million)
Table 189 China: Diagnostic Specialty Antibodies Market Size for Blood-borne Infections, by Type, 2020–2029 (USD Million)
Table 190 Regulatory Approvals for Antigen Test Kits for COVID-19 in Japan
Table 191 Japan: Diagnostic Specialty Antibodies Market Size, by Type, 2020–2029 (USD Million)
Table 192 Japan: Diagnostic Specialty Antibodies Market Size, by Clonality, 2020–2029 (USD Million)
Table 193 Japan: Diagnostic Specialty Antibodies Market Size, by Technique, 2020–2029 (USD Million)
Table 194 Japan: Diagnostic Specialty Antibodies Market Size, by Conjugate, 2020–2029 (USD Million)
Table 195 Japan: Diagnostic Specialty Antibodies Market Size, by Application, 2020–2029 (USD Million)
Table 196 Japan: Diagnostic Specialty Antibodies Market Size for Infectious Diseases, by Type, 2020–2029 (USD Million)
Table 197 Japan: Diagnostic Specialty Antibodies Market Size for Respiratory Infections, by Type, 2020–2029 (USD Million)
Table 198 Japan: Diagnostic Specialty Antibodies Market Size for Parasitic Infections, by Type, 2020–2029 (USD Million)
Table 199 Japan: Diagnostic Specialty Antibodies Market Size for GI Infections, by Type, 2020–2029 (USD Million)
Table 200 Japan: Diagnostic Specialty Antibodies Market Size for Blood-borne Infections, by Type, 2020–2029 (USD Million)
Table 201 List of Regulatory Approvals for COVID-19 Test Kits Containing Antibodies From The Indian Council of Medical Research (ICMR)
Table 202 List of Product Launches of COVID-19 Test Kits Containing Antibodies
Table 203 India: Diagnostic Specialty Antibodies Market Size, by Type, 2020–2029 (USD Million)
Table 204 India: Diagnostic Specialty Antibodies Market Size, by Clonality, 2020–2029 (USD Million)
Table 205 India: Diagnostic Specialty Antibodies Market Size, by Technique, 2020–2029 (USD Million)
Table 206 India: Diagnostic Specialty Antibodies Market Size, by Conjugate, 2020–2029 (USD Million)
Table 207 India: Diagnostic Specialty Antibodies Market Size, by Application, 2020–2029 (USD Million)
Table 208 India: Diagnostic Specialty Antibodies Market Size for Infectious Diseases, by Type, 2020–2029 (USD Million)
Table 209 India: Diagnostic Specialty Antibodies Market Size for Respiratory Infections, by Type, 2020–2029 (USD Million)
Table 210 India: Diagnostic Specialty Antibodies Market Size for Parasitic Infections, by Type, 2020–2029 (USD Million)
Table 211 India: Diagnostic Specialty Antibodies Market Size for GI Infections, by Type, 2020–2029 (USD Million)
Table 212 India: Diagnostic Specialty Antibodies Market Size for Blood-borne Infections, by Type, 2020–2029 (USD Million)
Table 213 Total COVID-19 Cases (As of 21st December 2021)
Table 214 Rest of Asia-Pacific: Diagnostic Specialty Antibodies Market Size, by Type, 2020–2029 (USD Million)
Table 215 Rest of Asia-Pacific: Diagnostic Specialty Antibodies Market Size, by Clonality, 2020–2029 (USD Million)
Table 216 Rest of Asia-Pacific: Diagnostic Specialty Antibodies Market Size, by Technique, 2020–2029 (USD Million)
Table 217 Rest of Asia-Pacific: Diagnostic Specialty Antibodies Market Size, by Conjugate, 2020–2029 (USD Million)
Table 218 Rest of Asia-Pacific: Diagnostic Specialty Antibodies Market Size, by Application, 2020–2029 (USD Million)
Table 219 Rest of Asia-Pacific: Diagnostic Specialty Antibodies Market Size for Infectious Diseases, By Type, 2020–2029 (USD Million)
Table 220 Rest of Asia-Pacific: Diagnostic Specialty Antibodies Market Size for Respiratory Infections, by Type, 2020–2029 (USD Million)
Table 221 Rest of Asia-Pacific: Diagnostic Specialty Antibodies Market Size for Parasitic Infections, By Type, 2020–2029 (USD Million)
Table 222 Rest of Asia-Pacific: Diagnostic Specialty Antibodies Market Size for GI Infections, by Type, 2020–2029 (USD Million)
Table 223 Rest of Asia-Pacific: Diagnostic Specialty Antibodies Market Size for Blood-borne Infections, by Type, 2020–2029 (USD Million)
Table 224 Latin America Total COVID-19 Cases (As of 21st December 2021)
Table 225 Latin America: Diagnostic Specialty Antibodies Market Size, by Type, 2020–2029 (USD Million)
Table 226 Latin America: Diagnostic Specialty Antibodies Market Size, by Clonality, 2020–2029 (USD Million)
Table 227 Latin America: Diagnostic Specialty Antibodies Market Size, by Technique, 2020–2029 (USD Million)
Table 228 Latin America: Diagnostic Specialty Antibodies Market Size, by Conjugate, 2020–2029 (USD Million)
Table 229 Latin America: Diagnostic Specialty Antibodies Market Size, by Application, 2020–2029 (USD Million)
Table 230 Latin America: Diagnostic Specialty Antibodies Market Size for Infectious Diseases, by Type, 2020–2029 (USD Million)
Table 231 Latin America: Diagnostic Specialty Antibodies Market Size for Respiratory Infections, By Type, 2020–2029 (USD Million)
Table 232 Latin America: Diagnostic Specialty Antibodies Market Size for Parasitic Infections, by Type, 2020–2029 (USD Million)
Table 233 Latin America: Diagnostic Specialty Antibodies Market Size for GI Infections, by Type, 2020–2029 (USD Million)
Table 234 Latin America: Diagnostic Specialty Antibodies Market Size for Blood-borne Infections, By Type, 2020–2029 (USD Million)
Table 235 COVID-19 Cases in the MEA Region (As of 15th December 2021)
Table 236 Middle East & Africa: Diagnostic Specialty Antibodies Market Size, by Type, 2020–2029 (USD Million)
Table 237 Middle East & Africa: Diagnostic Specialty Antibodies Market Size, by Clonality, 2020–2029 (USD Million)
Table 238 Middle East & Africa: Diagnostic Specialty Antibodies Market Size, by Technique, 2020–2029 (USD Million)
Table 239 Middle East & Africa: Diagnostic Specialty Antibodies Market Size, by Conjugate, 2020–2029 (USD Million)
Table 240 Middle East & Africa: Diagnostic Specialty Antibodies Market Size, by Application, 2020–2029 (USD Million)
Table 241 Middle East & Africa: Diagnostic Specialty Antibodies Market Size for Infectious Diseases, by Type, 2020–2029 (USD Million)
Table 242 Middle East & Africa: Diagnostic Specialty Antibodies Market Size for Respiratory Infections, by Type, 2020–2029 (USD Million)
Table 243 Middle East & Africa: Diagnostic Specialty Antibodies Market Size for Parasitic Infections, By Type, 2020–2029 (USD Million)
Table 244 Middle East & Africa: Diagnostic Specialty Antibodies Market Size for GI Infections, by Type, 2020–2029 (USD Million)
Table 245 Middle East & Africa: Diagnostic Specialty Antibodies Market Size for Blood-borne Infections, by Type, 2020–2029 (USD Million)
Table 246 Recent Developments, by Company, 2018—2021
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Size Estimation
Figure 7 Global Diagnostic Specialty Antibodies Market Size, by Type, 2022–2029 (USD Million)
Figure 8 Global Diagnostic Specialty Antibodies Market Size, by Clonality, 2022–2029 (USD Million)
Figure 9 Global Diagnostic Specialty Antibodies Market Size, by Technique, 2022–2029 (USD Million)
Figure 10 Global Diagnostic Specialty Antibodies Market Size, by Conjugate, 2022–2029 (USD Million)
Figure 11 Global Diagnostic Specialty Antibodies Market Size, by Application, 2022–2029 (USD Million)
Figure 12 Global Diagnostic Specialty Antibodies Market Size, by Geography
Figure 13 Market Dynamics
Figure 14 Estimated Incidence Rate for Different Types of Cancer in 2020
Figure 15 Global Diagnostic Specialty Antibodies Market Size, by Type, 2022–2029 (USD Millions)
Figure 16 Global Diagnostic Specialty Antibodies Market Size, by Clonality, 2022–2029 (USD Million)
Figure 17 Global Diagnostic Specialty Antibodies Market Size, by Application, 2022–2029 (USD Million)
Figure 18 Global Diagnostic Specialty Antibodies Market Size, by Technique, 2022–2029, (USD Million)
Figure 19 Global Diagnostic Specialty Antibodies Market Size, by Conjugate, 2022–2029 (USD Million)
Figure 20 Global Diagnostic Specialty Antibodies Market Size, by Region, 2022–2029 (USD Million)
Figure 21 Geographic Snapshot: North America Diagnostic Specialty Antibodies Market
Figure 22 Geographic Snapshot: Europe Diagnostic Specialty Antibodies Market
Figure 23 Estimated Percentage of New Cancer Cases in Spain (2020)
Figure 24 Geographic Snapshot: Asia-Pacific Diagnostic Specialty Antibodies Market
Figure 25 COVID-19 Vaccination Status in MEA Region
Figure 26 Key Growth Strategies Adopted by Leading Players, 2018–2021
Figure 27 Diagnostic Specialty Antibodies Market: Competitive Benchmarking (Based on Type)
Figure 28 Diagnostic Specialty Antibodies Market: Competitive Benchmarking (Based on Clonality)
Figure 29 Diagnostic Specialty Antibodies Market: Competitive Benchmarking (Based on Conjugation)
Figure 30 Diagnostic Specialty Antibodies Market: Competitive Benchmarking (Based on Geography)
Figure 31 Market Share Analysis: Diagnostic Specialty Antibodies Market, 2020
Figure 32 Abcam Plc: Financial Snapshot, 2020
Figure 33 F. Hoffman-La Roche AG Ltd: Financial Snapshot, 2020
Figure 34 Bio-Rad Laboratories, Inc.: Financial Snapshot, 2020
Figure 35 Merck KGaA: Financial Overview, 2020
Figure 36 Agilent Technologies, Inc: Financial Snapshot, 2020
Figure 37 Becton, Dickinson and Company: Financial Snapshot, 2021
Figure 38 Bio-Techne Corporation: Financial Snapshot, 2021
Figure 39 Thermo Fisher Scientific, Inc.: Financial Overview, 2020
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Monoclonal Antibodies Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Jun-2024
Livestock Diagnostics Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: May-2024
Europe Cancer Diagnostics Market- Opportunity Analysis And Industry Forecast (2024-2031)
Published Date: Feb-2024
